Do We Need HER-2/neu Testing for All Patients with Primary Breast Carcinoma?

Cancer

Volumn 98, Issue 12, 2003, Pages 2547-2553

  Taucher, Susanne ^a   Rudas, Margaretha ^a   Mader, Robert M ^a   Gnant, Michael ^a   Dubsky, Peter ^a   Bachleitner, Thomas ^a   Roka, Sebastian ^a   Fitzal, Florian ^a   Kandioler, Daniela ^a   Sporn, Emanuel ^a   Friedl, Josef ^a   Mittlböck, Martina ^a   Jakesz, Raimund ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Correlation; Estrogen receptor; Fluorescence in situ hybridization; Grading; HER 2 neu; Immunohistochemistry; Progesterone receptor; Prognosis

Indexed keywords

ESTROGEN RECEPTOR; NEU DIFFERENTIATION FACTOR; PROGESTERONE RECEPTOR;

ADULT; AGE; AGED; ANALYTICAL EQUIPMENT; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CLINICAL PRACTICE; CORRELATION COEFFICIENT; COST CONTROL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; HORMONE RESPONSE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; TUMOR VOLUME;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL; CARCINOMA, LOBULAR; DNA PROBES; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; LYMPH NODES; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0345098483     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11828     Document Type: Article

References (23)

1. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.
2. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-712.
3. Bamberger AM, Milde-Langosch K, Schulte HM, Loning T. Progesterone receptor isoforms, PR-B and PR-A, in breast cancer: correlations with clinicopathologic tumor parameters and expression of AP-1 factors. Horm Res. 2000;54:32-37.
4. Konecny G, Pauletti G, Pegram M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst. 2003;95:142-153.
5. Yamauchi H, O'Neill A, Gelman R, et al. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol. 1997;15:2518-2525.
6. Berger MS, Locher GW, Saurer S, et al. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res. 1988;48:1238-1243.
7. Querzoli P, Marchetti E, Fabris G, et al. Immunohistochemical expression of c-erbB-2 in human breast cancer by monoclonal antibody: correlation with lymph node and ER status. Tumori. 1990;76:461-464.
8. Sutterlin MW, Haller A, Gassel AM, et al. The correlation of c-erbB-2 oncoprotein and established prognostic factors in human breast cancer. Anticancer Res. 2000;20:5083-5088.
9. Colleoni M, Rotmensz N, Robertson C, et al. Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol. 2002;13:273-279.
10. Tubbs R, Skacel M, Pettay J, et al. Interobserver interpretative reproducibility of GOLDFISH, a first generation gold-facilitated autometallographic bright field in situ hybridization assay for HER-2/neu amplification in invasive mammary carcinoma. Am J Surg Pathol. 2002;26:908-913.
11. Reiner A, Neumeister B, Spona J, et al. Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. Cancer Res. 1990;50:7057-7061.
12. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403-410.
13. Benz CC, Scott GK, Sarup JC, et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat. 1993;24:85-95.
14. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a Phase III randomized trial. J Clin Oncol. 2001;19:3808-3816.
15. Tagliabue E, Menard S, Robertson JF, Harris L. c-erbB-2 expression in primary breast cancer. Int J Biol Markers. 1999;14:16-26.
16. Bertheau P, Steinberg SM, Merino MJ. C-erbB-2, p53, and nm23 gene product expression in breast cancer in young women: immunohistochemical analysis and clinicopathologic correlation. Hum Pathol. 1998;29:323-329.
17. Milde-Langosch K, Bamberger AM, Rieck G, Kelp B, Loning T. Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotype. Breast Cancer Res Treat. 2001;67:61-70.
18. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol. 2001;19:3817-3827.
19. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol. 1999;17:1974-1982.
20. Allred DC, Swanson PE. Testing for erbB-2 by immunohistochemistry in breast cancer. Am J Clin Pathol. 2000;113:171-175.
21. Tubbs RR, Pettay JD, Roche PC, et al. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol. 2001;19:2714-2721.
22. Pauletti G, Dandekar S, Rong H, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000;18:3651-3664.
23. Cell Markers and Cytogenetics Committees, College of American Pathologists. Clinical laboratory assays for HER-2/neu amplification and overexpression: quality assurance, standardization, and proficiency testing. Arch Pathol Lab Med. 2002;126:803-808.